Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADRO Aduro Biotech		$10.93	$4.51 ▼ $20.20	$236.61M	0.4	162,237 shs	171,500 shs
APTX Aptinyx	$0.10 +3.1%	$0.08	$0.01 ▼ $0.72	N/A	1.27	1.32 million shs	231,100 shs
KALV KalVista Pharmaceuticals	$11.57 +0.6%	$12.69	$7.21 ▼ $16.88	$488.14M	0.88	745,801 shs	346,976 shs
SBBP Strongbridge Biopharma	$2.00	$2.09	$1.85 ▼ $4.26	$135.66M	1.58	866,464 shs	684,684 shs
XOMA XOMA	$25.48 +3.6%	$24.46	$13.48 ▼ $27.00	$296.59M	0.58	21,504 shs	17,398 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADRO Aduro Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
APTX Aptinyx	0.00%	0.00%	0.00%	0.00%	-33.75%
KALV KalVista Pharmaceuticals	-1.29%	-4.96%	-2.87%	-7.33%	+39.90%
SBBP Strongbridge Biopharma	0.00%	0.00%	0.00%	0.00%	0.00%
XOMA XOMA	+1.40%	-6.15%	-2.42%	+23.57%	+27.08%

Secret Bull Market Starts in This Unusual Sector (Ad)

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADRO Aduro Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
APTX Aptinyx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	3.9629 of 5 stars	3.5	1.0	0.0	4.6	2.8	2.5	0.6
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XOMA XOMA	3.4881 of 5 stars	3.5	2.0	0.0	3.0	2.0	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADRO Aduro Biotech	N/A	N/A	N/A	N/A
APTX Aptinyx	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	3.00	Buy	$26.33	127.60% Upside
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A
XOMA XOMA	3.00	Buy	$74.00	190.42% Upside

Current Analyst Ratings

Latest APTX, XOMA, KALV, SBBP, and ADRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
2/16/2024	XOMA XOMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$74.00
2/14/2024	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $24.00
2/13/2024	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $35.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADRO Aduro Biotech	$17.26M	0.00	N/A	N/A	$4.07 per share	0.00
APTX Aptinyx	$1M	N/A	N/A	N/A	$0.57 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.71 per share	N/A
SBBP Strongbridge Biopharma	$30.73M	4.41	N/A	N/A	$0.98 per share	2.04
XOMA XOMA	$4.76M	62.31	N/A	N/A	$7.72 per share	3.30

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADRO Aduro Biotech	-$82.37M	-$5.15	N/A	N/A	N/A	-230.92%	-101.73%	-22.35%	N/A
APTX Aptinyx	-$64.85M	-$0.98	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	-$92.91M	-$3.15	N/A	N/A	N/A	N/A	-86.06%	-72.65%	7/5/2024 (Estimated)
SBBP Strongbridge Biopharma	-$45.08M	-$0.78	N/A	N/A	N/A	-115.67%	-66.82%	-36.21%	N/A
XOMA XOMA	-$40.83M	-$4.04	N/A	N/A	N/A	-886.91%	-25.17%	-17.08%	5/14/2024 (Estimated)

Latest APTX, XOMA, KALV, SBBP, and ADRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/11/2024	Q3 2024	KALV KalVista Pharmaceuticals	-$0.75	-$0.84	-$0.09	-$0.84	N/A	N/A
3/8/2024	Q4 2023	XOMA XOMA	-$0.36	-$0.49	-$0.13	$0.89	$1.01 million	$1.83 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADRO Aduro Biotech	N/A	N/A	N/A	N/A	N/A
APTX Aptinyx	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A	N/A
XOMA XOMA	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADRO Aduro Biotech	N/A	8.91	8.91
APTX Aptinyx	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	5.44	5.44
SBBP Strongbridge Biopharma	0.38	3.00	2.95
XOMA XOMA	1.34	8.68	8.68

Ownership

Institutional Ownership

Company	Institutional Ownership
ADRO Aduro Biotech	49.93%
APTX Aptinyx	N/A
KALV KalVista Pharmaceuticals	N/A
SBBP Strongbridge Biopharma	52.03%
XOMA XOMA	95.92%

Insider Ownership

Company	Insider Ownership
ADRO Aduro Biotech	5.90%
APTX Aptinyx	10.97%
KALV KalVista Pharmaceuticals	12.30%
SBBP Strongbridge Biopharma	5.10%
XOMA XOMA	7.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADRO Aduro Biotech	152	16.21 million	N/A	Optionable
APTX Aptinyx	12	N/A	N/A	Not Optionable
KALV KalVista Pharmaceuticals	118	42.19 million	37.00 million	Optionable
SBBP Strongbridge Biopharma	72	67.83 million	N/A	Optionable
XOMA XOMA	13	11.64 million	10.80 million	Optionable

APTX, XOMA, KALV, SBBP, and ADRO Headlines

Source	Headline
	XOMA (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average of $19.93 americanbankingnews.com - April 17 at 2:58 AM
	XOMA Co. (NASDAQ:XOMA) Shares Sold by Stonepine Capital Management LLC marketbeat.com - April 9 at 9:43 PM
	XOMA Corporation Announces Closing of Tender Offer globenewswire.com - April 3 at 9:00 AM
	XOMA Declares Quarterly Preferred Stock Dividends globenewswire.com - March 21 at 7:30 AM
	XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. globenewswire.com - March 19 at 4:05 PM
	KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE businesswire.com - March 13 at 11:49 AM
	XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 investorplace.com - March 8 at 1:03 PM
	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value finance.yahoo.com - March 8 at 7:51 AM
	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value globenewswire.com - March 8 at 7:30 AM
	XOMA to Present at Upcoming Investor Conferences in March globenewswire.com - February 28 at 7:30 AM
	KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE businesswire.com - February 19 at 11:03 AM
	Compare with Maple Leaf Green World Inc (4HV0) msn.com - February 18 at 12:30 PM
	XOMA to acquire Kinnate Biopharma thepharmaletter.com - February 17 at 10:21 AM
	XOMA Mar 2024 20.000 put finance.yahoo.com - February 17 at 10:21 AM
	XOMA Jun 2024 25.000 call finance.yahoo.com - February 17 at 10:21 AM
	Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma benzinga.com - February 16 at 1:37 PM
	XOMA Agrees to Acquire Kinnate Biopharma marketwatch.com - February 16 at 8:36 AM
	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right finance.yahoo.com - February 16 at 8:36 AM
	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right finance.yahoo.com - February 16 at 8:36 AM
	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right globenewswire.com - February 16 at 8:00 AM
	With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors finance.yahoo.com - January 20 at 2:06 PM
	XOMA To Pay $1 Mln Milestone To LadRx As FDA Accepts Zevra's Arimoclomol NDA For NPC markets.businessinsider.com - January 11 at 10:48 PM
	FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx tmcnet.com - January 11 at 5:46 PM
	Xoma to Make $1M Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol marketwatch.com - January 11 at 5:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aduro Biotech

NASDAQ:ADRO

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Aptinyx

NASDAQ:APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

KalVista Pharmaceuticals

NASDAQ:KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Strongbridge Biopharma

NASDAQ:SBBP

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

XOMA

NASDAQ:XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial